(Q34611762)

English

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase III clinical trial

0 references

multiple sclerosis

0 references

Hans-Peter Hartung

5

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Frederik Barkhof

8

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ivana Kovářová

0 references

David H. Miller

6

object named as

David H Miller

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

ORCID Public Data File 2021

3

object named as

Chris H Polman

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Mark S Freedman

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gilles Edan

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Xavier Montalbán

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ernst-Wilhelm Radü

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Carola Metzig

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lars Bauer

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Vivian Lanius

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Rupert Sandbrink

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Christoph Pohl

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

BENEFIT Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

10 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

987-997

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the functional assessment of multiple sclerosis quality of life instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

How much can we learn from long-term extension trials in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cortical motor reorganization after a single clinical attack of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional magnetic resonance imaging and cognition at the very early stage of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MRI techniques to monitor MS evolution: the present and the future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain atrophy, interferon beta, and treatment trials in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MRI as an outcome in multiple sclerosis clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970237-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(09)70237-6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34611762&oldid=1981626480"